Navigation Links
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Date:6/2/2009

symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague
  • A third generation rPA anthrax vaccine.

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical info
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
2. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
3. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Delivery of the Report will take 2-3 ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... on Global and Chinese Hemodialysis Machine industry. The ... Machine including its classification, application and manufacturing technology. ... manufacturers of Hemodialysis Machine listing their product specification, ...
(Date:7/24/2014)... 24, 2014 Cancer patients in the west of ... cancer treatment closer to home when a new radiotherapy center ... Medical Systems (NYSE: VAR ) has been selected ... in June for four TrueBeam™ medical linear accelerators. ... and efficient radiotherapy and radiosurgery treatments, will replace older treatment ...
(Date:7/24/2014)... July 24, 2014  Blueprint Medicines (Blueprint), a leader ... cancer patients, today announced the appointment of Jeffrey ... joins Blueprint from Algeta ASA, where he served on ... the acquisition by Bayer. Mr. Albers succeeds Alexis ... Partner at Third Rock Ventures, who will remain an ...
Breaking Medicine Technology:Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2
... 2011 Volcano Corporation (NASDAQ: VOLC ), a ... designed to enhance the diagnosis and treatment of coronary and ... operating results for the third quarter of fiscal 2011 on ... conference call to discuss its financial results and operating activities ...
... Oct. 17, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. ... the "Company"), a developer, manufacturer and distributor of botanical ... today announced the results of its annual general meeting ... 2011 in Harbin, China. At the Annual ...
Cached Medicine Technology:Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2China Botanic Announces Results of Annual General Meeting 2
(Date:7/24/2014)... As the age of marriage and ... as a way to ensure future family building options ... advancing reproductive age. Vitrification technology, a fast freeze method ... technology that allows a woman to have multiple eggs ... which are then stored for future use. When circumstances ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
(Date:7/24/2014)... 2014 In a recent report by CBS ... put an end to criminal penalties associated with possession of ... for marijuana reform in Washington DC, giving it one of ... replaces criminal penalties for possession of one ounce of marijuana ... possession of more than an ounce of marijuana remain criminal ...
(Date:7/24/2014)... from Penn Medicine shows that incisionless transcatheter aortic ... stay by 30 percent and has no impact ... conventional transfemoral TAVR, which requires an incision in ... the current issue of Circulation: Cardiovascular Interventions ... aortic valve without a traditional open-heart surgical approach. ...
(Date:7/24/2014)... PROVIDENCE, R.I. Lynn E. Taylor, M.D., director ... states in the July, 2014 Rhode Island ... C" that eliminating hepatitis c virus infection (hep ... benefits, enhance capacity to address other health challenges, ... HCV in the United States, Taylor says, include ...
Breaking Medicine News(10 mins):Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Washington D.C. Decriminalizes Marijuana 2Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... , FRIDAY, March 25 (HealthDay News) -- A small army ... of sick and dying animals from a rural North Carolina ... More than 400 animals -- 17 species in all, ... had been living in squalor with a middle-aged couple claiming ...
... FRIDAY, March 25 (HealthDay News) -- People looking for a ... joints sometimes turn to biking. Rather than a 30-minute jog ... hours on the bike, with little or no joint strain. ... physical activity raise a new problem: How to keep the ...
... Aurora, Colo. (March 24, 2011)A research team at the University ... be used to diagnose colon cancer earlier. It is possible ... the cancer. Colon cancer is the third most common cancer ... it, according to the American Cancer Society. This enzyme biomarker ...
... The US Food and Drug Administration announced today that ... the treatment of patients with metastatic melanoma. It is the ... with advanced melanoma. Ipilimumab uses a novel approach known ... attack cancer. The therapy, originally known as anti-CTLA-4, was developed ...
... Research Chair Peter Shizgal who investigates the roots ... recognized by his peers with the prestigious Prix Adrien ... Psychology and a member of the Centre for Studies ... qubcoise pour la recherche en psychologie (Quebec Society for ...
... , FRIDAY, March 25 (HealthDay News) -- A poor diet ... postmenopausal women, a new study has found. Researchers analyzed ... found that deficiencies in more than a single nutrient were ... Risk increased 44 percent with deficiencies in three nutrients. ...
Cached Medicine News:Health News:Animal 'Hoarding' Often Tied to Mental Illness 2Health News:Animal 'Hoarding' Often Tied to Mental Illness 3Health News:Animal 'Hoarding' Often Tied to Mental Illness 4Health News:Cyclists Urged to Prep Their Bodies for the Long Haul 2Health News:Cyclists Urged to Prep Their Bodies for the Long Haul 3Health News:University of Colorado team identifies new colon cancer marker 2Health News:Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma 2Health News:Peter Shizgal distinguished by his peers 2Health News:Poor Eating Habits May Lead to Anemia in Older Women 2
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer ... day, 7 days per week. With rugged ... footprint. Powerwave breaks the barrier of traditional ... reliably. One instrument can easily read up ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
Medicine Products: